FDA Expands Acetaminophen, NSAID Labeling Beyond Tentative Final Rule
This article was originally published in The Tan Sheet
Executive Summary
FDA's final rule for OTC products containing acetaminophen or nonsteroidal anti-inflammatory drugs requires warnings and revisions that go beyond changes the agency proposed in a 2006 tentative final rule
You may also be interested in...
No GRASE For Ibuprofen, No Future In OTC Internal Analgesic Monograph
Nonprescription products containing ibuprofen can now only be marketed in the US through NDAs. No companies took advantage of a proposed ibuprofen addition to the the internal analgesic, antipyretic and antirheumatic OTC monograph, issued in 2002.
No GRASE For Ibuprofen, No Future In OTC Internal Analgesic Monograph
Nonprescription products containing ibuprofen can now only be marketed in the US through NDAs. No companies took advantage of a proposed ibuprofen addition to the the internal analgesic, antipyretic and antirheumatic OTC monograph, issued in 2002.
Alka-Seltzer Antacid Will 'Plop, Plop Fizz, Fizz' Without Aspirin
In advance of a US FDA advisory panel meeting on the safety of OTC monograph antacid/aspirin products, Bayer is removing aspirin from its pioneering Alka-Seltzer effervescent indigestion products. Bayer's Andre Schmidt talks about the safety advantages and consumer trends that helped spur the change.